(Q47996177)

English

The effect of adjuvants on the immune response induced by a DBL4ɛ-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria.

scientific article published on 26 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

The effect of adjuvants on the immune response induced by a DBL4ɛ-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Plasmodium falciparum

0 references

0 references

malaria vaccine

1 reference

based on heuristic

inferred from title

Morten Agertoug Nielsen

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Thor G. Theander

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

V V Pinto

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

L M Joergensen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

M Dahlbäck

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

M Resende

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

S B Ditlev

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

E M Agger

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

D E Arnot

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

0 references

publication date

26 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

572-579

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22122859%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of plasmodium falciparum-infected erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Cloning the P. falciparum gene encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface of parasitized human erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Parasite sequestration in Plasmodium falciparum malaria: spleen and antibody modulation of cytoadherence of infected erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Characterization of proteoglycans of human placenta and identification of unique chondroitin sulfate proteoglycans of the intervillous spaces that mediate the adherence of Plasmodium falciparum-infected erythrocytes to the placenta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

The low sulfated chondroitin sulfate proteoglycans of human placenta have sulfate group-clustered domains that can efficiently bind Plasmodium falciparum-infected erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Plasmodium falciparum-infected erythrocytes adhere both in the intervillous space and on the villous surface of human placenta by binding to the low-sulfated chondroitin sulfate proteoglycan receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Malaria in pregnancy: pathogenesis and immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Maternal antibodies block malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Evidence for the involvement of VAR2CSA in pregnancy-associated malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

New adjuvants for human vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Mechanism of action of clinically approved adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Toll or toll-free adjuvant path toward the optimal vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Plasmodium falciparum parasites expressing pregnancy-specific variant surface antigens adhere strongly to the choriocarcinoma cell line BeWo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

CD36 selection of 3D7 Plasmodium falciparum associated with severe childhood malaria results in reduced VAR4 expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Plasmodium falciparum: VAR2CSA expressed during pregnancy-associated malaria is partially resistant to proteolytic cleavage by trypsin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Surface co-expression of two different PfEMP1 antigens on single plasmodium falciparum-infected erythrocytes facilitates binding to ICAM1 and PECAM1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Several domains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Strain-transcendent immune response to recombinant Var2CSA DBL5-ε domain block P. falciparum adhesion to placenta-derived BeWo cells under flow conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

High efficacy of anti DBL4ɛ-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

The effectiveness of different rat IgG subclasses as IgE-blocking antibodies in the rat basophil leukaemia cell model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

The kinetics of antibody binding to Plasmodium falciparum VAR2CSA PfEMP1 antigen and modelling of PfEMP1 antigen packing on the membrane knobs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.11.068

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47996177&oldid=1726616872"